189 related articles for article (PubMed ID: 6685916)
1. [Prevention of vascular complications in polycythemia vera and primary thrombocythemia treated with low doses of acetylsalicylic acid].
Fröhli P; Graf C; Rhyner K
Schweiz Med Wochenschr; 1983 Nov; 113(44):1622-7. PubMed ID: 6685916
[TBL] [Abstract][Full Text] [Related]
2. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
3. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
4. Erythromelalgia and vascular complications in polycythemia vera.
Michiels JJ
Semin Thromb Hemost; 1997; 23(5):441-54. PubMed ID: 9387203
[TBL] [Abstract][Full Text] [Related]
5. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
6. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
Barbui T; Finazzi G
Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
[TBL] [Abstract][Full Text] [Related]
7. Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia.
Michiels JJ; Berneman Z; Schroyens W; van Urk H
Ann Hematol; 2003 Mar; 82(3):153-9. PubMed ID: 12634947
[TBL] [Abstract][Full Text] [Related]
8. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
Landolfi R; Cipriani MC; Novarese L
Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
[TBL] [Abstract][Full Text] [Related]
9. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
Elliott MA; Tefferi A
Br J Haematol; 2005 Feb; 128(3):275-90. PubMed ID: 15667529
[TBL] [Abstract][Full Text] [Related]
11. The use of aspirin in polycythaemia vera and primary thrombocythaemia.
Willoughby S; Pearson TC
Blood Rev; 1998 Mar; 12(1):12-22. PubMed ID: 9597194
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera].
Nagai M; Tasaka T; Kamano H; Ohnishi H; Taoka T; Ikeda K; Kubota Y; Tanaka T; Irino S
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3267-70. PubMed ID: 3196045
[TBL] [Abstract][Full Text] [Related]
13. Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.
Kayrak M; Acar K; Yazici M; Kaya C; Ayhan SS; Gok H
Clin Appl Thromb Hemost; 2009; 15(4):465-6. PubMed ID: 18160579
[TBL] [Abstract][Full Text] [Related]
14. Low-dose aspirin in polycythemia vera.
Dutrillaux F; Maynadié M; Carli PM
N Engl J Med; 2004 Apr; 350(16):1683-5; author reply 1683-5. PubMed ID: 15088322
[No Abstract] [Full Text] [Related]
15. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
[TBL] [Abstract][Full Text] [Related]
16. Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Landolfi R; Di Gennaro L
Haematologica; 2008 Mar; 93(3):331-5. PubMed ID: 18310537
[No Abstract] [Full Text] [Related]
17. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
18. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients.
Brusamolino E; Canevari A; Salvaneschi L; Merante S; Bernasconi C
Cancer Treat Rep; 1984 Nov; 68(11):1339-42. PubMed ID: 6541969
[TBL] [Abstract][Full Text] [Related]
19. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.
Michiels JJ; Berneman ZN; Schroyens W; Van Vliet HH
Platelets; 2004 Mar; 15(2):67-84. PubMed ID: 15154599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]